HighMorph: De Novo Cyclic Peptide Sequence Design via Protein-Protein Interaction Recapitulation

Cyclic peptides have emerged as a compelling class of bioactive scaffolds, but de novo design of target-binding cyclic peptides from protein structures remains challenging. Here, we present HighMorph, an interaction-guided framework that combines protein-protein interaction information with artificial intelligence for rational cyclic peptide design. HighMorph integrates Monte Carlo tree search with a Transformer-based policy-value network to efficiently explore cyclic peptide sequence space, while incorporating explicit atomic-level hydrogen bond constraints extracted from reference protein-protein complexes to guide sequence optimization. The framework is systematically validated on two clinically relevant targets, programmed death-ligand 1 (PD-L1) and kallikrein-related peptidase 4 (KLK4). Notably, 33.3% and 40% of the generated candidates are active against PD-L1 and KLK4, respectively, with active cyclic peptides exhibiting micromolar binding affinities (approximately 10-6 M). These results validate our approach for cyclic peptide design. Additionally, interaction analysis provides insights for developing therapeutics targeting challenging protein interfaces.